Take­da con­tin­ues post-Shire sell­off, inch­ing clos­er to $10B goal

The Take­da sell­off con­tin­ues.

In the lat­est of the Japan­ese phar­ma’s post-merg­er trim­mings, Take­da has sold off a port­fo­lio of “non-core” over-the-counter and pre­scrip­tion prod­ucts mar­ket­ed ex­clu­sive­ly in Asia to the South Ko­re­an-based Cell­tri­on. The de­part­ing port­fo­lio gen­er­at­ed $140 mil­lion in net 2018 sales. Take­da will re­ceive $266 mil­lion, with an­oth­er $12 mil­lion avail­able in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER